skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation

Journal Article · · PLoS ONE
 [1];  [2];  [2];  [3];  [1];  [1];  [1];  [4];  [2];  [2];  [2];  [2];  [5];  [5];  [5];  [1];  [4];  [5];  [5];  [5] more »;  [6];  [5];  [5];  [5];  [1];  [1];  [4] « less
  1. Celgene Corporation, San Diego, CA (United States). Dept. of Inflammation Research
  2. Celgene Corporation, San Diego, CA (United States). Dept. of Chemistry
  3. Pfizer Corporation, San Diego, CA (United States)
  4. Celgene Corporation, San Diego, CA (United States). Dept. of Pharmacology
  5. Celgene Corporation, San Diego, CA (United States). Dept. of Biochemistry
  6. Kissei Pharmaceutical Company, Nagano (Japan). Dept. of Corporate Planning and Strategy
+ Show Author Affiliations

Autoantibodies and the immunoreceptors to which they bind can contribute to the pathogenesis of autoimmune diseases such as rheumatoid arthritis (RA). Spleen Tyrosine Kinase (Syk) is a non-receptor tyrosine kinase with a central role in immunoreceptor (FcR) signaling and immune cell functionality. Syk kinase inhibitors have activity in antibody-dependent immune cell activation assays, in preclinical models of arthritis, and have progressed into clinical trials for RA and other autoimmune diseases. Here we describe the characterization of a novel triazolopyridine-based Syk kinase inhibitor, CC-509. This compound is a potent inhibitor of purified Syk enzyme, FcR-dependent and FcR-independent signaling in primary immune cells, and basophil activation in human whole blood. CC-509 is moderately selective across the kinome and against other non-kinase enzymes or receptors. Importantly, CC-509 was optimized away from and has modest activity against cellular KDR and Jak2, kinases that when inhibited in a preclinical and clinical setting may promote hypertension and neutropenia, respectively. In addition, CC-509 is orally bioavailable and displays dose-dependent efficacy in two rodent models of immune-inflammatory disease. In passive cutaneous anaphylaxis (PCA), CC-509 significantly inhibited skin edema. Moreover, CC-509 significantly reduced paw swelling and the tissue levels of pro-inflammatory cytokines RANTES and MIP-1α in the collagen-induced arthritis (CIA) model. In summary, CC-509 is a potent, moderately selective, and efficacious inhibitor of Syk that has a differentiated profile when compared to other Syk compounds that have progressed into the clinic for RA.

Research Organization:
Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
Sponsoring Organization:
USDOE Office of Science (SC)
Grant/Contract Number:
AC02-05CH11231
OSTI ID:
1627777
Journal Information:
PLoS ONE, Vol. 11, Issue 1; ISSN 1932-6203
Publisher:
Public Library of ScienceCopyright Statement
Country of Publication:
United States
Language:
English

References (54)

Gini Coefficient:  A New Way To Express Selectivity of Kinase Inhibitors against a Family of Kinases † journal November 2007
Refinement of Macromolecular Structures by the Maximum-Likelihood Method journal May 1997
Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy journal January 2013
Targeting Syk as a treatment for allergic and autoimmune disorders journal July 2004
Comprehensive analysis of kinase inhibitor selectivity journal October 2011
B cells move to centre stage: novel opportunities for autoimmune disease treatment journal July 2006
Thrombopoietin: a pan-hematopoietic cytokine journal February 2002
R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation journal August 2006
Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling. journal December 1995
The immunomodulatory adapter proteins DAP12 and Fc receptor  -chain (FcR ) regulate development of functional osteoclasts through the Syk tyrosine kinase journal April 2004
Deletion of Syk in Neutrophils Prevents Immune Complex Arthritis journal September 2011
An efficient rapid system for profiling the cellular activities of molecular libraries journal February 2006
Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis journal January 2010
The Syk Protein Tyrosine Kinase Is Essential for Fcγ Receptor Signaling in Macrophages and Neutrophils journal July 1998
Establishment and Characterization of a Novel Human Rheumatoid Fibroblast-Like Synoviocyte Line, MH7A, Immortalized with SV40 T Antigen journal December 1998
Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry journal January 1990
The Syk kinase as a therapeutic target in leukemia and lymphoma journal March 2011
Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis journal August 2012
Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis journal October 2011
Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells: Gö6976 is a JAK2 and FLT3 Inhibitor journal September 2006
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis journal January 2010
Highly Miniaturized Formats for In Vitro Drug Metabolism Assays Using Vivid® Fluorescent Substrates and Recombinant Human Cytochrome P450 Enzymes journal February 2005
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 journal April 2010
Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors journal February 2012
Differential Expression and Molecular Associations of Syk in Systemic Lupus Erythematosus T Cells journal November 2008
Janus Kinases: An Ideal Target for the Treatment of Autoimmune Diseases journal December 2013
Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies: Pharmacokinetics of fostamatinib in three phase I studies journal June 2013
I G G F C R ECEPTORS journal April 2001
Involvement of Fcγ receptor IIIA genotypes in susceptibility to rheumatoid arthritis journal April 2000
The arthritis severity locus Cia5a regulates the expression of inflammatory mediators including Syk pathway genes and proteases in pristane-induced arthritis journal January 2012
The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation: Fostamatinib-induced BP elevation journal April 2014
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor journal September 2007
Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk journal April 2009
A Novel Spleen Tyrosine Kinase Inhibitor Blocks c-Jun N-Terminal Kinase-Mediated Gene Expression in Synoviocytes journal February 2006
Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus (SLE) T Cell Signaling journal August 2013
Syk tyrosine kinase required for mouse viability and B-cell development journal November 1995
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms journal April 2010
Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406 journal June 2007
Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure–activity relationships of pyrimidine-5-carboxamide derivatives journal August 2005
Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis journal April 2013
Analysis of Fcγ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B journal January 2006
Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice journal April 2000
Multiparametric scaling of diffraction intensities journal April 2003
Interleukin-3 Activates Syk in a Human Myeloblastic Leukemia Cell Line, AML193 journal November 1997
Tumour necrosis factor-alpha potentiates CR3-induced respiratory burst by activating p38 MAP kinase in human neutrophils journal August 2001
Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production journal October 2005
Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis journal July 2013
Evolving concepts of rheumatoid arthritis journal May 2003
Genetic deficiency of Syk protects mice from autoantibody-induced arthritis journal January 2010
Syk kinase as a treatment target for therapy in autoimmune diseases journal September 2007
Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcεRI or FcγRI journal August 2003
Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice journal April 2000
Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12) journal February 2001
The Serological Diagnosis of Rheumatoid Arthritis journal March 2009

Similar Records

Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A
Journal Article · Tue Apr 19 00:00:00 EDT 2016 · Journal of Inflammation Research · OSTI ID:1627777
+9 more
Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
Journal Article · Wed Jan 03 00:00:00 EST 2018 · Journal of Medicinal Chemistry · OSTI ID:1627777
+32 more
Oleanolic acid acetate inhibits rheumatoid arthritis by modulating T cell immune responses and matrix-degrading enzymes
Journal Article · Fri Jan 01 00:00:00 EST 2016 · Toxicology and Applied Pharmacology · OSTI ID:1627777
+10 more

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
Science & Technology - Other Topics